Purple Biotech (PPBT) Competitors $2.38 -0.11 (-4.42%) Closing price 04/8/2025 03:56 PM EasternExtended Trading$2.38 +0.00 (+0.17%) As of 04/8/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. EQ, CING, ABVC, GLYC, BCTX, INAB, NXTC, ME, MTVA, and MRKRShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Equillium (EQ), Cingulate (CING), ABVC BioPharma (ABVC), GlycoMimetics (GLYC), BriaCell Therapeutics (BCTX), IN8bio (INAB), NextCure (NXTC), 23andMe (ME), MetaVia (MTVA), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Equillium Cingulate ABVC BioPharma GlycoMimetics BriaCell Therapeutics IN8bio NextCure 23andMe MetaVia Marker Therapeutics Purple Biotech (NASDAQ:PPBT) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Does the media refer more to PPBT or EQ? In the previous week, Equillium had 1 more articles in the media than Purple Biotech. MarketBeat recorded 1 mentions for Equillium and 0 mentions for Purple Biotech. Equillium's average media sentiment score of 0.88 beat Purple Biotech's score of 0.00 indicating that Equillium is being referred to more favorably in the news media. Company Overall Sentiment Purple Biotech Neutral Equillium Positive Do institutionals and insiders hold more shares of PPBT or EQ? 9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 30.3% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is PPBT or EQ more profitable? Purple Biotech has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Purple BiotechN/A -55.86% -44.67% Equillium -10.05%-20.68%-10.77% Do analysts prefer PPBT or EQ? Purple Biotech currently has a consensus price target of $33.00, indicating a potential upside of 1,286.55%. Equillium has a consensus price target of $3.00, indicating a potential upside of 547.67%. Given Purple Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Purple Biotech is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community believe in PPBT or EQ? Equillium received 19 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 80.00% of users gave Equillium an outperform vote. CompanyUnderperformOutperformPurple BiotechOutperform Votes1794.44% Underperform Votes15.56%EquilliumOutperform Votes3680.00% Underperform Votes920.00% Which has more risk & volatility, PPBT or EQ? Purple Biotech has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Which has stronger valuation and earnings, PPBT or EQ? Equillium has higher revenue and earnings than Purple Biotech. Equillium is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPurple BiotechN/AN/A-$19.88M-$5.25-0.45Equillium$41.10M0.40-$13.34M-$0.23-2.01 SummaryEquillium beats Purple Biotech on 11 of the 16 factors compared between the two stocks. Remove Ads Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.17M$6.08B$5.08B$6.91BDividend YieldN/A2.88%5.33%4.21%P/E Ratio-0.276.5321.3317.05Price / SalesN/A185.43349.5885.97Price / CashN/A65.6738.1534.64Price / Book0.095.356.053.66Net Income-$19.88M$141.19M$3.19B$247.27M7 Day Performance-10.53%-10.64%-7.80%-8.86%1 Month Performance-15.30%-20.11%-6.79%-12.84%1 Year PerformanceN/A-22.14%0.32%-10.80% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech1.4155 of 5 stars$2.38-4.4%$33.00+1,286.6%N/A$3.17MN/A-0.2720EQEquillium2.6399 of 5 stars$0.39-3.2%$3.00+664.7%-75.9%$13.90M$41.10M-2.8040Gap UpCINGCingulate2.8162 of 5 stars$4.30-1.1%$16.00+272.1%+257.4%$13.81MN/A-0.2920Gap UpABVCABVC BioPharma1.155 of 5 stars$1.06+23.3%N/A-28.4%$13.75M$509,788.00-1.2330Gap DownHigh Trading VolumeGLYCGlycoMimetics1.1916 of 5 stars$0.21-3.8%N/A-92.9%$13.55M$10,000.000.0050Analyst ForecastNews CoverageGap UpBCTXBriaCell Therapeutics1.1266 of 5 stars$3.65-8.1%$32.00+776.7%-91.2%$13.54MN/A-0.278INABIN8bio2.2339 of 5 stars$0.17-15.3%$6.00+3,514.5%-86.2%$13.49MN/A-0.2220NXTCNextCure3.8844 of 5 stars$0.48-3.7%$3.50+628.7%-83.9%$13.45MN/A-0.2390Gap DownME23andMe1.2415 of 5 stars$0.50-35.3%$9.40+1,787.6%-94.8%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeMTVAMetaVia1.9613 of 5 stars$1.54-2.2%$12.00+679.2%N/A$13.33MN/A0.0010Positive NewsGap DownMRKRMarker Therapeutics3.8784 of 5 stars$1.23-3.1%$13.50+997.6%-77.7%$13.17M$3.31M0.0060 Remove Ads Related Companies and Tools Related Companies Equillium Competitors Cingulate Competitors ABVC BioPharma Competitors GlycoMimetics Competitors BriaCell Therapeutics Competitors IN8bio Competitors NextCure Competitors 23andMe Competitors MetaVia Competitors Marker Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 4/9/2025 by MarketBeat.com Staff From Our PartnersElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
